AlphaLife Sciences，a pioneer in the fusion of life sciences and AI computer science, is committed to building AuroraPrime, a globally leading AI-enabled integrated clinical research platform. Utilizing cutting-edge AI models, cloud computing, and big data technology, it fully supports clinical trials and real-world studies, accelerating innovation and enhancing market competitiveness. AuroraPrime's integrated platform features an open and flexible technical architecture, seamlessly integrating data and documents throughout the clinical research process, ensuring data quality and compliance. Utilizing advanced AI technology from both domestic and international sources, we provide intelligent support for the entire process of global multicenter clinical research. This enhances clinical operational efficiency, achieves process automation and intelligent decision-making, empowers the acceleration of pharmaceutical products to market, and establishes competitive barriers for enterprises.
Alice HsuSVP of Clinical Technology Service & Consulting
In 2020, a group of senior technology and product experts from Google and Verily China decided to start a business and delve into the intelligent digitalization of life science clinical research. With the goal of building a SaaS platform for life science and consumer health fields through world-leading computer technology, AlphaLife Sciences was officially established in August 2020. With the vision of "Use technology to advance innovation in life science and consumer health. Faster, more accessible and evidence-based," the AlphaLife team quickly grew and attracted many technology talents from leading global IT companies and senior industry experts from the life sciences field. With the gradual launch of AlphaLife's innovative products, more and more leading life science innovation and development companies, as well as ecosystem partners, choose AlphaLife, collaborate in multiple ways, and jointly explore the future of intelligent digitalization in clinical research.
Rapid Development & Investor Trusted
AlphaPrime Life Sciences Group was officially established by former Google talents.
Completed seed round financing.
Officially launched AuroraPrime 1.0.
Completed Series A financing of over 10 millions of USD.
Officially launched AuroraPrime 2.0.
AlphaPrime Life Sciences Group located HQ in Singapore
Completed Series A+ financing of tens of millions of USD.
US office (AlphaLife Sciences) was officially opened.
AuroraPrime completed integration with OpenAI.
Part of Our Investment Partners
Lightspeed China Partners
B Capital Group
Sharon Chen | CEO
Sharon Chen is currently the CEO of AlphaPrime Life Sciences Group. She oversees the group’s business operation including business and product strategies, talent acquisition, financing and public relations.
Prior to joining AlphaPrime, she was the head of Verily China (Alphabet’s life science arm) and the Engineering Site Lead of Google Shanghai. She began her Google career as a software engineer at the headquarter in the Bay Area since 2005 and advanced positions to head of Google Engineering Shanghai Site. Prior to Google and Verily, Sharon held tech lead positions at Experian and Brocade.
Sharon has been working in the tech field for more than 20 years. She has received her B.S. degree major in Automation from Shanghai Jiaotong University and a M.S degree major in Computer Science from Texas A&M University.
Pengcheng Xu | CTO
Mr.Xu Pengcheng, a key technical expert at Verily China, founded AlphaPrime Life Sciences Group in 2020 and currently serves as CTO, responsible for technical research and development, as well as internal operations and management.
Prior to joining AlphaPrime, Pengcheng worked at Google for 12 years and was the first local engineer at Google China. After leaving Google, he served as the Chief System Architect at Verily China, an entrepreneurial company focused on life sciences under the umbrella of Google's parent company.
Mr.Xu Pengcheng graduated from the Department of Computer Science and Technology at Peking University with a bachelor's degree.
Gavin Zhang | CBO
As the co-founder, Gavin Zhang is currently the CBO of AlphaPrime Life Sciences Group responsible for the overall sales, marketing and business strategy.
Before joining AlphaPrime, Gavin worked for Medidata as the head of channel sales in Asia Pacific region. He also worked in sales, channel and R&D management positions in Microsoft, Oracle, EMC, NetApp and other companies in the last 20 plus years.
Gavin graduated from Tianjin University of Finance and economics with a bachelor's degree in economics and a master's degree in Business Administration from Peking University and University of Leuven Ghent.
Bogong Zhu | CPO
As a key technical expert at Verily China, Bogong Zhu co-founded AlphaPrime Life Sciences Group in 2020. He currently serves as the Vice President of Technology and Chief Product Officer, responsible for product and technology development.
Prior to joining AlphaPrime, Bogong had over 13 years of experience at Google, where he worked on various projects in the Ads and Cloud AI domains. After leaving Google, he served as a technical supervisor at Verily China, an entrepreneurial company focused on life sciences under the umbrella of Google's parent company.
Bogong Zhu earned his bachelor's degree in Software Engineering from East China Normal University and an MBA degree from Shanghai Jiao Tong University.
Alice Hsu | SVP of Clinical Technology Service & Consulting
Alice Hsu is currently the SVP of Clinical Technology Services & Consulting at AlphaPrime Life Sciences Group. Her responsibilities includes lead of Clinical Technology team, provide clinical trial operations knowledge as well system development and strategies support to the organization. To therefore bring in efficiency and quality services for clients in the use of AlphaPrime’s integrated system platform.
Prior to joining AlphaPrime, Alice has over 15 years of experiences in the CRO industry with positions held in IQVIA, Covance, WuXi Clinical and PPD respectively where she was based in Taipei, Singapore and Shanghai. Her main scope of work and responsibilities over the years included from technical delivery of projects to leadership roles in clinical operation and project management departments.
Alice graduated from Johns Hopkins University Bloomberg School of Public Health and University of Illinois, Urbana Champaign with MHS and M.S. majored in Nutritional Sciences and Immunophysiology.
Névine is a highly accomplished thought leader in the fields of biostatistics and data science with extensive experience across all phases of drug development. Névine had a 25-year career in senior roles at GlaxoSmithKline and AstraZeneca where she also led the Enterprise Data & Analytics initiative. She has been a key contributor to development strategies for over 200 drug projects across oncology, cardiovascular, metabolic, respiratory, inflammation, and renal diseases. She has been a reviewer for The Lancet and has over 30 peer reviewed publications to her name. She is a strategic consultant to several organisations including scientific data consortia such as ctDNA. She advised FDA (Office of the Principal Deputy Commissioner) on the application of real-world evidence to COVID19. She serves on the Scientific Advisory Board of ANOVA, ZS Associates, and Intelligencia. She was a Board member of CDISC for 6 years.
Dr. Ruyi He is the Chief Medical Officer of RemeGen CO., Ltd. and Chief Scientist of SDIC Fund Management CO., LTD and former Chief Scientist at the Center for Drug Evaluation at the National Medical Products Administration (NMPA). Dr. He joined NMPA in July 2016, after having worked at the US Food and Drug Administration (FDA) for more than 17 years. Dr. He joined the US Center for Drug Evaluation and Research (CDER) at the US FDA in 1999 as a Medical Officer in the Division of Gastrointestinal and Coagulation Drug Products and later served as the Acting Deputy Director in the division for years. Dr. He received his medical degree from China Medical University. He completed his intern and residency training in Internal Medicine at Howard University Hospital in Washington, DC. and received his clinical and research training at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH) in Bethesda, Maryland. Dr. He is a licensed, board-certified physician in Internal Medicine in the USA.